Scpharmaceuticals (NASDAQ:SCPH) posted its quarterly earnings data on Tuesday. The company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12, Fidelity Earnings reports.
Shares of NASDAQ SCPH traded up $0.08 on Wednesday, reaching $5.24. 30,700 shares of the company traded hands, compared to its average volume of 56,580. Scpharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $7.85. The company has a 50 day moving average of $5.66 and a 200 day moving average of $4.89. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $97.92 million, a PE ratio of -3.30 and a beta of 0.79.
SCPH has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. HC Wainwright initiated coverage on shares of Scpharmaceuticals in a research note on Tuesday, October 15th. They set a “buy” rating and a $13.00 price objective for the company. Finally, ValuEngine raised shares of Scpharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $8.00.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.